Siponimod Patent Expiration
Siponimod is Used for treating multiple sclerosis. It was first introduced by Novartis Pharmaceuticals Corp
Siponimod Patents
Given below is the list of patents protecting Siponimod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mayzent | US11944602 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | Apr 23, 2036 | Novartis |
| Mayzent | US12533340 | Treatment Of Autoimmune Disease In A Patient Receiving Additionally A Beta-Blocker | Apr 23, 2036 | Novartis |
| Mayzent | US12071402 | Immunosuppressant formulations | Jan 05, 2032 | Novartis |
| Mayzent | US8492441 | Dosage regimen of an S1P receptor agonist | Nov 30, 2030 | Novartis |
| Mayzent | US7939519 | Immunosuppresant compounds and compositions | Aug 27, 2028 | Novartis |
Siponimod's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Siponimod:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |